Codiak Biosciences Inc
CDAK
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $10.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.91 |
| Beta | 3.93 |
| Outstanding Shares | 25,159,757 |
Return
| Return on Equity | -75.10% |
|---|---|
| Return on Assets | -21.75% |
| Return on Invested Capital | -44.44% |
Valuation & Multiples
| P/E Ratio | -0.03 |
|---|---|
| PEG | 0.14 |
| Price to Sales | 0.06 |
| Price to Book Ratio | 0.06 |
| Enterprise Value to Revenue | 0.32 |
| Enterprise Value to EBIT | -0.2 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 5.76 |
| Debt to Equity | 1.61 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Codiak Biosciences Inc
105 employees
CEO: Douglas Williams Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unm...